111 related articles for article (PubMed ID: 10857997)
1. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma.
Small EJ; Figlin R; Petrylak D; Vaughn DJ; Sartor O; Horak I; Pincus R; Kremer A; Bowden C
Invest New Drugs; 2000 May; 18(2):193-7. PubMed ID: 10857997
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
[TBL] [Abstract][Full Text] [Related]
3. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of KW2189 in patients with advanced malignant melanoma.
Markovic SN; Suman VJ; Vukov AM; Fitch TR; Hillman DW; Adjei AA; Alberts SR; Kaur JS; Braich TA; Leitch JM; Creagan ET
Am J Clin Oncol; 2002 Jun; 25(3):308-12. PubMed ID: 12040295
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma.
Kish JA; Ensley JF; al-Sarraf M
Am J Clin Oncol; 1990 Feb; 13(1):17-8. PubMed ID: 2305717
[TBL] [Abstract][Full Text] [Related]
8. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of depsipeptide in refractory metastatic renal cell cancer.
Stadler WM; Margolin K; Ferber S; McCulloch W; Thompson JA
Clin Genitourin Cancer; 2006 Jun; 5(1):57-60. PubMed ID: 16859580
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Dirix L; Catimel G; Koier I; Provè A; Schrijvers D; Joossens E; De Bruijn E; Ardiet C; Evene E; Dumortier A
Anticancer Drugs; 1995 Feb; 6(1):53-63. PubMed ID: 7756684
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
14. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
[TBL] [Abstract][Full Text] [Related]
15. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
16. Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
Witte RS; Elson P; Bryan GT; Trump DL
Invest New Drugs; 1992 Apr; 10(1):51-4. PubMed ID: 1535065
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
19. Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma.
Clark JI; Gaynor ER; Martone B; Budds SC; Manjunath R; Flanigan RC; Waters WB; Sosman JA
Clin Cancer Res; 1999 Sep; 5(9):2374-80. PubMed ID: 10499607
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.
Motzer R; Scher H; Bajorin D; Sternberg C; Bosl GJ
Invest New Drugs; 1990 Nov; 8(4):391-2. PubMed ID: 2084073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
